Dianthus Therapeutics Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Dianthus Therapeutics Inc.
Former names: Magenta Therapeutics, Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: New York
Headquarters state / province: New York
Headquarters country: United States
Fiscal year end: December
Ticker symbol: DNTH
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001690585
Wikidata ID: Q99744291

Board of directors

Follow this board

Alison Frances Lawton · Director
Since 2023
Anne McGeorge · Director
Since 2023
David Roy Witzke · Director
Since 2024
Jonathan Violin · Director
Since 2023
Lei Meng · Director
Since 2023
Leon O. Moulder Jr. · Director
Since 2023
Marino Garcia · Director · CEO AND PRESIDENT
Since 2023
Michael David Gregory · Director
Since 2024
Paula Soteropoulos · Director
Since 2023
Peter Evan Harwin · Director Overboarded
Since 2023
Simon Read · Director
Since 2025
Steven J. Romano · Director
Since 2024
Sujay Kango · Director
Since 2025
Tomas Kiselak · Director Overboarded
Since 2023

Chief executives

Marino Garcia · CEO and President

Since September 2023

Director election results

Annual meeting of May 21, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

9 of this board's directors also sit on 17 other boards. 17 are in the same sector.

Shared director Other board Same sector +1 more in the list below

Crescent Biopharma Inc. Same sector
via Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
Korsana Biosciences Inc. Same sector
via Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
Spyre Therapeutics Inc. Same sector
via Alison Frances Lawton, Peter Evan Harwin and Tomas Kiselak
Viridian Therapeutics Inc. Same sector
via Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
Zenas BioPharma Inc. Same sector
via Leon O. Moulder Jr., Peter Evan Harwin and Tomas Kiselak
Jade Biosciences Inc. Same sector
via Peter Evan Harwin and Tomas Kiselak
Oruka Therapeutics Inc. Same sector
via Peter Evan Harwin and Tomas Kiselak
AgomAb Therapeutics NV Same sector
via Marino Garcia
Cogent Biosciences Inc. Same sector
via Peter Evan Harwin
Damora Therapeutics Inc. Same sector
via Peter Evan Harwin
Lite Strategy Inc. Same sector
via Sujay Kango
ProQR Therapeutics N.V. Same sector
via Alison Frances Lawton
Rallybio Corporation Same sector
via Paula Soteropoulos
Starling Oncology Inc. Same sector
via Anne McGeorge
X4 Pharmaceuticals Inc. Same sector
via Alison Frances Lawton
Zai Lab Limited Same sector
via Leon O. Moulder Jr.
uniQure N.V. Same sector
via Paula Soteropoulos

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $79,210,853; 72 sales by 8 insiders

Date	Insider	Transaction	Shares	Price	Value
Nov 12, 2026	Savitz Ryan Officer (EVP, CFO & CBO)	Option exercise	+1,339	$21.77	$29,150
Nov 12, 2026	Savitz Ryan Officer (EVP, CFO & CBO)	Option exercise	+16,385	$22.07	$361,617
Nov 12, 2026	Savitz Ryan Officer (EVP, CFO & CBO)	Open-market sale	−17,724	$90.56	$1,605,085
Nov 11, 2026	Savitz Ryan Officer (EVP, CFO & CBO)	Option exercise	+1,744	$21.77	$37,967
Nov 11, 2026	Savitz Ryan Officer (EVP, CFO & CBO)	Option exercise	+1,300	$22.07	$28,691
Nov 11, 2026	Savitz Ryan Officer (EVP, CFO & CBO)	Open-market sale	−3,044	$90.03	$274,051
Nov 10, 2026	Savitz Ryan Officer (EVP, CFO & CBO)	Option exercise	+1,301	$21.77	$28,323
Nov 10, 2026	Savitz Ryan Officer (EVP, CFO & CBO)	Option exercise	+1,260	$22.07	$27,808
Nov 10, 2026	Savitz Ryan Officer (EVP, CFO & CBO)	Open-market sale	−2,561	$90.14	$230,849
Nov 9, 2026	Savitz Ryan Officer (EVP, CFO & CBO)	Option exercise	+29,276	$17.88	$523,455
Nov 9, 2026	Savitz Ryan Officer (EVP, CFO & CBO)	Option exercise	+20,608	$21.77	$448,636
Nov 9, 2026	Savitz Ryan Officer (EVP, CFO & CBO)	Option exercise	+40,430	$22.07	$892,290
Nov 9, 2026	Savitz Ryan Officer (EVP, CFO & CBO)	Option exercise	+10,399	$8.44	$87,768
Nov 9, 2026	Savitz Ryan Officer (EVP, CFO & CBO)	Open-market sale	−300	$85.16	$25,548
Nov 9, 2026	Savitz Ryan Officer (EVP, CFO & CBO)	Open-market sale	−700	$86.70	$60,690

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Dianthus Therapeutics Inc.

Who is the CEO of Dianthus Therapeutics Inc.?

Marino Garcia has been Dianthus Therapeutics Inc.'s CEO and President since September 2023.

How many directors are on Dianthus Therapeutics Inc.'s board?

Dianthus Therapeutics Inc.'s board has 14 directors: Alison Frances Lawton, Anne McGeorge, David Roy Witzke, Jonathan Violin, Lei Meng, Leon O. Moulder Jr., Marino Garcia, Michael David Gregory, Paula Soteropoulos, Peter Evan Harwin and 4 others.

Are Dianthus Therapeutics Inc. insiders buying or selling shares?

Over the last 12 months, Dianthus Therapeutics Inc. insiders made no open-market purchases and sold $79.2 million of shares in 72 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Dianthus Therapeutics Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="dianthus-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.